No doubt 2011 was an interesting year for stem cell companies. Of the publicly listed stem cell companies, almost all lost money and few retained their value at the close of the stock markets last year.
The stem cell industry is truly at an inception point and this downturn is set to change. As clinical trials progress, we are beginning to see the clinical evidence that stem cell therapies really work. Stem cells for drug discovery and toxicology applications are delivering the promise to address the pharmaceutical industry's drug development pipeline.
The field of stem cells is extremely heterogeneous and can be confusing to navigate. Find out how the stem cells industry is set to change and get more insights from our expert trainer, Dr Erik Miljan, at the 3 Day MBA in Stem Cells. Dr Miljan has over 9 years' experience in stem cells and initiated, implemented and delivered the operational and management strategy leading to the first ever stem cell-based product approved for clinical trial in the UK.
The course will provide you with a comprehensive overview of the stem cells industry and allow you to learn from past successes and failures within the field. Don't miss this exciting opportunity – register today.